Page last updated: 2024-11-13

1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone is a **synthetic organic molecule** with a complex structure containing:

* **A thiophene ring**: A five-membered ring with a sulfur atom.
* **A nitro group**: A functional group with a nitrogen atom bonded to two oxygen atoms.
* **A ketone group**: A functional group with a carbonyl group (C=O).
* **A phenyl ring**: A six-membered ring with six carbon atoms.
* **Two fluorine atoms**: On the phenyl ring.

While the exact details of its specific applications in research are not available without further context or a specific research paper, its structure suggests potential uses in several areas, including:

* **Pharmaceutical research:** The presence of a nitro group, a thiophene ring, and a ketone group are often found in molecules with biological activity. This molecule could be a starting point for developing new drugs targeting various receptors or enzymes.
* **Material science:** The combination of fluorine, sulfur, and nitrogen atoms can contribute to interesting properties such as conductivity, thermal stability, or optical properties. It could be used in developing new materials for applications like organic electronics or sensors.
* **Agricultural chemistry:** The presence of a thiophene ring and a ketone group are commonly found in pesticides and herbicides. This molecule could be a potential lead compound for developing new agricultural chemicals.

**To understand the exact importance of this molecule in research, more information is needed, such as:**

* **The specific research project it is used in.**
* **Its biological activity, if any.**
* **Its chemical properties and reactivity.**

Therefore, it's impossible to definitively state its significance without further context. However, the complex structure of this molecule suggests it could be valuable in several research areas.

1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone: a USP7 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46931953
CHEMBL ID2159498
SCHEMBL ID2680945
MeSH IDM0572141

Synonyms (36)

Synonym
chembl2159498 ,
bdbm50393440
S7133
1247819-59-5
1-(5-(2,4-difluorophenylthio)-4-nitrothiophen-2-yl)ethanone
HY-13865
CS-1860
p 22077
1-[5-(2,4-difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone
1-[5-[(2,4-difluorophenyl)thio]-4-nitro-2-thienyl]-ethanone
SCHEMBL2680945
p22077
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethan-1-one
AC-32695
AKOS024458186
1-[5-[(2,4-difluorophenyl)thio]-4-nitro-2-thienyl]ethanon
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl) ethanone
1-[5-(2,4-difluorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone
DTXSID40677376
1-{5-[(2,4-difluorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one
mfcd22580421
HMS3653G09
1-[5-(2,4-difluorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone
SW219709-1
FT-0707469
BCP07858
Z1614727651
EX-A1445
p-22077
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone
CCG-267643
C71981
AS-55923
NCGC00263556-10
A899043
EN300-6492974
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ubiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)IC50 (µMol)11.77670.13004.04628.0000AID1434737; AID1491542; AID694815
Ubiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)IC50 (µMol)8.70004.30006.50008.7000AID694816
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ubiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)EC50 (µMol)4.20004.20005.46678.0000AID1195671
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
monoubiquitinated protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
transcription-coupled nucleotide-excision repairUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
DNA alkylation repairUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
proteolysisUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
protein ubiquitinationUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of protein stabilityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of circadian rhythmUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
negative regulation of gluconeogenesisUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
rhythmic processUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
protein stabilizationUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of DNA-binding transcription factor activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
symbiont-mediated disruption of host cell PML bodyUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of signal transduction by p53 class mediatorUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
negative regulation of TORC1 signalingUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of telomere cappingUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
regulation of retrograde transport, endosome to GolgiUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
base-excision repairUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
proteolysisUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
DNA damage responseUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
response to xenobiotic stimulusUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
negative regulation of G2/M transition of mitotic cell cycleUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
positive regulation of cell growthUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
cellular response to UVUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
monoubiquitinated protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
negative regulation of apoptotic processUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
negative regulation of DNA-templated transcriptionUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damageUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
p53 bindingUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
cysteine-type endopeptidase activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
K48-linked deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
WD40-repeat domain bindingUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
PML bodyUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
chromosomeUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
nuclear bodyUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
protein-containing complexUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 7Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
SCF ubiquitin ligase complexUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase 47Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1434738Antiproliferative activity against human HCT116 cells expressing wild type p53 assessed as decrease in cell viability after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors.
AID1491542Inhibition of full-length recombinant USP7 (unknown origin) expressed in Sf9 cells using Ub-EKL as substrate preincubated for 30 mins followed by substrate addition by fluorescence based assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies.
AID694816Inhibition of USP47 by Ub-CHOP reporter assay2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.
AID694818Metabolic stability of the compound in rat plasma assessed as compound remaining at 1 uM after 3 hrs2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.
AID694819Inhibition of caspase 3 using DEVD-Rh110 as substrate incubated for 30 mins prior to substrate addition by fluorimetric analysis2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.
AID1434737Inhibition of USP7 (unknown origin) using Ub-Rho as substrate preincubated for 30 mins followed by substrate addition and subsequent incubation in dark for 3 hrs by fluorescence assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors.
AID1195671Inhibition of USP7 (unknown origin) by Ub-CHOP reporter assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Inhibiting the deubiquitinating enzymes (DUBs).
AID694815Inhibition of recombinant USP7 expressed in Sf9 cells by Ub-CHOP reporter assay2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.
AID694817Chemical stability of the compound assessed as GSH adduct formation at 133 uM2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's11 (55.00)24.3611
2020's9 (45.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.52 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]